Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 601 to 610 of 2194 total matches.

Palbociclib (Ibrance) for Metastatic Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015  (Issue 1475)
Table 1. Pharmacology Class CDK 4 and 6 inhibitor Formulation 75, 100, 125 mg capsules Route Oral ...
Palbociclib (Ibrance – Pfizer), an oral cyclin-dependent kinase inhibitor, has been approved by the FDA for use in combination with the aromatase inhibitor letrozole (Femara, and generics) for first-line treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. It is the first cyclin-dependent kinase inhibitor to become available in the US.
Med Lett Drugs Ther. 2015 Aug 17;57(1475):115-6 | Show Introduction Hide Introduction

Brexpiprazole (Rexulti) for Schizophrenia and Depression

   
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015  (Issue 1475)
when adherence is a problem.1 Table 1. Pharmacology Class Second-generation antipsychotic Mechanism ...
The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole (Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder (MDD). Aripiprazole (Abilify), a structurally similar second-generation antipsychotic also comarketed by Otsuka (with BMS), recently became available generically.
Med Lett Drugs Ther. 2015 Aug 17;57(1475):116-8 | Show Introduction Hide Introduction

Panobinostat (Farydak) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015  (Issue 1475)
-blind trial (PANORAMA1) in 768 patients with relapsed or refractory multiple myeloma who had received 1 ...
The FDA has approved panobinostat (Farydak – Novartis), an oral histone deacetylase (HDAC) inhibitor, for use in combination with bortezomib (Velcade) and dexamethasone for treatment of patients with multiple myeloma who have received at least 2 prior therapies including bortezomib and an immunomodulatory drug. It is the first HDAC inhibitor to be approved for this indication.
Med Lett Drugs Ther. 2015 Aug 17;57(1475):e118-119 | Show Introduction Hide Introduction

Lenvatinib (Lenvima) for Thyroid Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015  (Issue 1475)
inhibitor and in those who had not (median progression-free survival 15.1 and 18.7 months, respectively ...
The FDA has approved the oral multikinase inhibitor lenvatinib (Lenvima – Eisai) for treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer (papillary or follicular) refractory to radioactive iodine treatment.
Med Lett Drugs Ther. 2015 Aug 17;57(1475):e120-121 | Show Introduction Hide Introduction

Sacubitril/Valsartan (Entresto) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015  (Issue 1474)
for patients who cannot tolerate an ACE inhibitor.1 MECHANISM OF ACTION — Neprilysin is a neutral ...
The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular death and heart failure hospitalization in patients with heart failure with reduced ejection fraction. Sacubitril is the first neprilysin inhibitor to become available in the US.
Med Lett Drugs Ther. 2015 Aug 3;57(1474):107-9 | Show Introduction Hide Introduction

Rifaximin (Xifaxan) for Irritable Bowel Syndrome with Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015  (Issue 1474)
to treat IBS-C that has not responded to fiber and laxatives.1,2 MECHANISM OF ACTION — Rifaximin ...
Rifaximin (Xifaxan – Salix), a minimally absorbed oral antibiotic approved previously to treat travelers' diarrhea and to reduce the risk of recurrent hepatic encephalopathy, has now been approved by the FDA for treatment of irritable bowel syndrome with diarrhea (IBS-D). Eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist, was also recently approved for IBS-D and will be reviewed in a future issue.
Med Lett Drugs Ther. 2015 Aug 3;57(1474):109-11 | Show Introduction Hide Introduction

Polidocanol (Varithena) for Varicose Veins

   
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015  (Issue 1474)
and stripping.1 A meta-analysis of 13 randomized controlled trials in ˃3000 patients with great saphenous ...
An injectable foam formulation of the sclerosing agent polidocanol (Varithena – Provensis/BTG) has been approved by the FDA for treatment of incompetent veins and visible varicosities of the great saphenous vein system. It is the first foam therapy to be approved for this indication, but polidocanol and other sclerosants have been used for years as foam formulations compounded by physicians. Polidocanol is also available in a liquid formulation (Asclera) to treat smaller veins. Sodium tetradecyl sulfate (Sotradecol) is FDA-approved in a liquid formulation for use in...
Med Lett Drugs Ther. 2015 Aug 3;57(1474):111-2 | Show Introduction Hide Introduction

In Brief: Duopa - A Carbidopa/Levodopa Enteral Suspension for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015  (Issue 1474)
.24 hours with immediaterelease tablets.1 Duopa is available in a 100-mL single-use cassette containing 4 ...
The FDA has approved Duopa (Abbvie), a carbidopa/levodopa enteral suspension, for treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). It has been available in Europe since 2001.In patients with advanced PD, emptying of the stomach may be delayed and unpredictable, which can affect the rate and amount of absorption of carbidopa/levodopa and its efficacy. To bypass the stomach, the new formulation is delivered through a nasojejunal (NJ) tube or percutaneous endoscopic gastrostomy with jejunal (PEG-J) tube.A randomized, double-blind, active-controlled, 12-week...
Med Lett Drugs Ther. 2015 Aug 3;57(1474):112 | Show Introduction Hide Introduction

Aptensio XR - Another Long-Acting Methylphenidate for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015  (Issue 1473)
of Aptensio XR for 2-4 weeks, followed by crossover treatment for 1 week each with placebo and the new ...
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.
Med Lett Drugs Ther. 2015 Jul 20;57(1473):101-3 | Show Introduction Hide Introduction

Prestalia - Another Combination for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015  (Issue 1473)
, and generics).1 Two other ACE inhibitor/calcium channel blocker combinations, benazepril/amlodipine (Lotrel ...
The FDA has approved Prestalia (Symplmed), an oral fixed-dose combination of the dihydropyridine calcium channel blocker amlodipine (Norvasc, and generics) and a new salt form of the angiotensin-converting enzyme (ACE) inhibitor perindopril, for treatment of hypertension in patients not adequately controlled on monotherapy or already taking both drugs, and in those just starting therapy who are likely to need multiple drugs to control their blood pressure. The new salt form (perindopril arginine) is more stable and has a longer shelf-life than perindopril erbumine (Aceon, and generics). Two...
Med Lett Drugs Ther. 2015 Jul 20;57(1473):103-4 | Show Introduction Hide Introduction